# reload+after+2024-01-23 01:43:08.889082
address1§480 Arsenal Way
address2§Suite 100
city§Watertown
state§MA
zip§02472
country§United States
phone§617 207 8979
website§https://www.acrivon.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
fullTimeEmployees§56
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Peter  Blume-Jensen M.D., Ph.D.', 'age': 60, 'title': 'Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 1005642, 'exercisedValue': 0, 'unexercisedValue': 1614527}, {'maxAge': 1, 'name': 'Ms. Kristina  Masson M.B.A., Ph.D.', 'age': 42, 'title': 'Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Rasmus  Holm-Jorgensen', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1001293, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eric J. Devroe Ph.D.', 'age': 45, 'title': 'Chief Operating Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 614779, 'exercisedValue': 0, 'unexercisedValue': 629016}, {'maxAge': 1, 'name': 'Ms. Katharine  Peterson CPA', 'title': 'Vice President of Finance & Accounting', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Adam D. Levy M.B.A., Ph.D.', 'title': 'Senior VP and Head of Investor Relations & Corporate Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bruce  Close', 'title': 'Vice President of Quality & Compliance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mary-Alice  Miller J.D.', 'age': 49, 'title': 'Chief Legal Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Parvin  Miah', 'title': 'VP & Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Erick  Gamelin M.D., Ph.D.', 'age': 65, 'title': 'Chief Medical Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 480723, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§8
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-3.1
exchange§NGM
quoteType§EQUITY
shortName§Acrivon Therapeutics, Inc.
longName§Acrivon Therapeutics, Inc.
firstTradeDateEpochUtc§1668522600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ec97dcba-7584-3161-bbe1-36f5f444af3c
gmtOffSetMilliseconds§-18000000
targetHighPrice§26.0
targetLowPrice§12.0
targetMeanPrice§21.13
targetMedianPrice§22.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§15.28
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
